Understanding the 2026 DVA Medicinal Cannabis Funding Changes for Clinics
The Australian Department of Veterans’ Affairs (DVA) is a government agency which provides support, compensation, and healthcare to current and former members of the Australian Defence Force. Currently, DVA provides partial or full funding for medicinal cannabis treatments for eligible patients.
However, in 2026, DVA introduced updates to its Medicinal Cannabis Framework that are likely to reshape how clinics deliver care to veteran patients. One of the most impactful changes that was introduced is a clear requirement that initial consultations must be conducted in person for a patient to be considered eligible for DVA-funded prescriptions (Department of Veterans’ Affairs, 2026a).
This is a particularly important change for clinics that have relied heavily on telehealth-led models – it represents a structural shift in how care must be delivered, documented, and justified under DVA funding pathways.
A Shift Away From Telehealth-Only Initiation
The updated framework makes it quite clear that telehealth models of care alone are no longer sufficient for initiating DVA-funded medicinal cannabis treatment. While remote care may still have a role in follow-up consultations, the first clinical assessment must now occur face-to-face with the prescribing doctor (Department of Veterans’ Affairs, 2026b). On the contrary, if a patient is unable to attend an in-person initial doctor’s consultation, they can still choose to go the telehealth route fully self-funded.
This requirement reflects a broader move toward tighter clinical oversight. The DVA has indicated that in-person consultations support more comprehensive assessments, clearer communication of risks, and stronger alignment with safe prescribing practices. From a clinic perspective, this places greater emphasis on physical presence, practitioner availability, and the ability to facilitate in-person care pathways.
Clinics that previously operated with a national telehealth footprint will need to reassess how they onboard new veteran patients. Without an in-person consultation, DVA funding is unlikely to be approved.
Operational Implications for Clinics
The immediate impact for most clinics is logistical. For years, telehealth clinics in this space have been marketing their remote care models as a selling point to patients. But now, patient acquisition strategies that direct individuals straight into telehealth consults may no longer align with DVA requirements. Instead, clinics will need to ensure that veterans can access an in-person appointment early in their journey.
For some providers, this may involve establishing physical clinic locations or partnering with existing practices to enable face-to-face assessments. For others, it may mean restructuring intake processes so that telehealth is positioned as a secondary step rather than the entry point.
There is also a documentation component to consider. The in-person consultation must demonstrate a thorough clinical assessment, including consideration of prior treatments and appropriateness for this pathway. This aligns with the DVA’s continued position that medicinal cannabis is not a first-line option and should only be considered after conventional approaches have been explored (Department of Veterans’ Affairs, 2026a).
Prescriber Considerations and Clinical Governance
The 2026 updates also reinforce the importance of prescribing oversight. Doctors involved in DVA-funded prescribing are expected to meet stricter criteria, and treatment decisions must be clearly justified within the framework.
For clinics, this raises the bar on clinical governance. Internal processes should support consistent assessment standards, appropriate patient selection, and clear documentation of clinical reasoning. The shift toward in-person initiation can be seen as part of a broader effort to reduce variability in prescribing practices and ensure alignment with national expectations.
Clinics that invest in strong governance frameworks and clear clinical protocols are likely to be better positioned to navigate these changes without disruption (The Medical Republic, 2026; RSL Australia, 2026).
Patient Experience and Access
From a patient perspective, the requirement for an in-person consultation may introduce an additional step, particularly for veterans in regional or remote areas. Clinics should be mindful of this when designing patient journeys and consider how to minimise friction while remaining compliant.
Clear communication at all steps (from the website, to the ads) will be essential. Veterans need to understand early in the process that an in-person appointment is required for DVA funding eligibility, and clinics should provide guidance on how and where this can be arranged.
At the same time, there is an opportunity to strengthen patient trust. Face-to-face consultations can support more meaningful clinical interactions, which may contribute to better engagement and continuity of care over time.
A More Structured Access Pathway
These changes signal a shift toward a more structured and clinically grounded access pathway for DVA-funded medicinal cannabis. Rather than limiting access outright, the framework introduces additional safeguards intended to support appropriate prescribing and patient safety.
For clinics, the key takeaway is clear: the model of care must evolve. Telehealth remains a valuable tool, but it can no longer function as the sole entry point for DVA-funded treatment.
Adapting early, whether through clinic expansion, partnerships, or revised patient flows, will be critical. Clinics that align their operations with the updated framework are more likely to maintain continuity in patient access while meeting compliance expectations.
Learn More
EQWELLIBRIYUM offers end-to-end consulting for organisations navigating the medicinal cannabis market in Australia. With strategic insights and operational frameworks that are designed to help you thrive, we’re here to help you. Learn more by contacting us today at hello@eqwellibriyum.com.
Substitution Regulations Download
Sign up to our mailing list to receive a complimentary outline of the substitution regulations per state and territory within Australia.
Reference List
Department of Veterans’ Affairs. Medicinal cannabis. Updated 16 February 2026. https://www.dva.gov.au/what-we-help-with/health-support/help-to-cover-healthcare-costs/manage-medicine-and-keep-costs-down/medicinal-cannabis
Department of Veterans’ Affairs. Updated medicinal cannabis framework supports safe and effective prescribing practices. 2026. https://www.dva.gov.au/providers/provider-news/updated-medicinal-cannabis-framework-supports-safe-and-effective-prescribing-practices
Department of Veterans’ Affairs. Medicinal cannabis framework – frequently asked questions. 2026. https://www.dva.gov.au/what-we-help-with/health-support/help-to-cover-healthcare-costs/manage-medicine-and-keep-costs-down/medicinal-cannabis/medicinal-cannabis-framework-frequently-asked-questions
The Medical Republic. DVA says no to telehealth cannabis prescribers. 2026. https://www.medicalrepublic.com.au/dva-says-no-to-telehealth-cannabis-prescribers/123296RSL Australia.
RSL welcomes DVA action on medicinal cannabis. 2026. https://www.rslaustralia.org/latest-news/rsl-welcomes-dva-action-on-medicinal-cannabis